Source: International Congress 2019 – Advances in COPD pharmacology
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
A. Mulvanny (Manchester, United Kingdom), C. Pattwell (Manchester, United Kingdom), J. Chomiak (Manchester, United Kingdom), T. Southworth (Manchester, United Kingdom), D. Singh (Manchester, United Kingdom). Validation of sputum supernatant biomarker assays in stable and exacerbating COPD subjects. 2039

Member's Comments

No comment yet.

Related content which might interest you: Repeatability of inflammatory analysis in induced sputum samples in COPD Source: Eur Respir J 2004; 24: Suppl. 48, 469s Year: 2004 An improved assay for detection of sputum periostin in patients with asthma Source: Virtual Congress 2020 – Phenotypes of asthma and COPD Year: 2020 Sputum biomarkers in stable COPD Source: Annual Congress 2011 - New mechanisms in airway disease Year: 2011 Usefulness of a panel of sputum markers in the evaluation of lung inflammation and functional impairment in symptomatic smokers and COPD patients Source: Annual Congress 2011 - Treatment strategies, systemic manifestations and biomarkers in airway diseases Year: 2011 Assessment of growth factors production from sputum cell culture and sputum supernatant in COPD patients Source: Annual Congress 2009 - Cell biology of lung disease Year: 2009 Simultaneous analysis of sputum and serum biomarkers in adult asthma Source: International Congress 2019 – Clinical implications of asthma management Year: 2019 Effectiveness of a panel of sputum markers in smokers with and without COPD to detect pulmonary progression towards functional impairment Source: Virtual Congress 2020 – Personalised treatment of obstructive diseases Year: 2020 Increased levels of osteopontin in sputum supernatant in patients with COPD Source: Annual Congress 2012 - Airway diseases: from invasive to noninvasive biomarkers Year: 2012 Differences in plasma and sputum biomarkers between COPD and COPD–asthma overlap Source: Eur Respir J 2014; 43: 421-429 Year: 2013 Proteomic derived biomarkers for COPD are present in induced sputum Source: Eur Respir J 2005; 26: Suppl. 49, 439s Year: 2005 Il-6 levels in sera and induced sputum of COPD patients during exacerbations and stable period Source: Eur Respir J 2005; 26: Suppl. 49, 284s Year: 2005 Differences in plasma and sputum biomarkers between COPD and COPD-asthma overlap Source: Annual Congress 2013 –Is it really asthma? Year: 2013 Alterations in sputum inflammatory markers during exacerbations for COPD patients with different stable state levels Source: International Congress 2019 – Host-microbe interactions in lung disease and exacerbations Year: 2019 Role of biomarkers in the assessment and phenotyping asthma and COPD Source: ERS Skills course - Biomarkers and functional assessment of obstructive lung diseases Year: 2017 Evaluating the sensitivity and specificity of NEATstik technology compared to an activity-based immunoassay in sputum samples from participants with COPD Source: Eur Respir J, 55 (5) 1902412; 10.1183/13993003.02412-2019 Year: 2020 A proteomic approach to the progression of COPD: protein expression profile in induced sputum samples Source: Eur Respir J 2006; 28: Suppl. 50, 824s Year: 2006 LTB4 in expired breath condensate and sputum supernatant in patients with COPD. The effects of reversibility Source: Eur Respir J 2003; 22: Suppl. 45, 476s Year: 2003 Is CRP really valid acute-phase inflammation reactant in all patients with sputum bacterial positive culture in acute exacerbation of COPD? Source: Annual Congress 2010 - COPD: systemic inflammation and comorbidities Year: 2010 Sputum biomarkers in COPD exacerbations Source: Annual Congress 2011 - Monitoring exacerbations of airway diseases Year: 2011 Quantitative analysis of potentially pathogenic microbes (PPMs) in the induced sputum of non-smoker COPD (NS-COPD) subjects Source: International Congress 2016 – Clinical and microbiological aspects of infections in COPD patients Year: 2016